JP2025183283A5 - - Google Patents

Info

Publication number
JP2025183283A5
JP2025183283A5 JP2025146941A JP2025146941A JP2025183283A5 JP 2025183283 A5 JP2025183283 A5 JP 2025183283A5 JP 2025146941 A JP2025146941 A JP 2025146941A JP 2025146941 A JP2025146941 A JP 2025146941A JP 2025183283 A5 JP2025183283 A5 JP 2025183283A5
Authority
JP
Japan
Prior art keywords
composition
dihydroquinoline
quinoline
pharmaceutically acceptable
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025146941A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025183283A (ja
Filing date
Publication date
Priority claimed from JP2023013779A external-priority patent/JP7387926B2/ja
Application filed filed Critical
Publication of JP2025183283A publication Critical patent/JP2025183283A/ja
Publication of JP2025183283A5 publication Critical patent/JP2025183283A5/ja
Pending legal-status Critical Current

Links

JP2025146941A 2022-02-01 2025-09-04 選択的エストロゲン受容体分解剤の調製のためのプロセス Pending JP2025183283A (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202263305520P 2022-02-01 2022-02-01
US63/305,520 2022-02-01
US202263409060P 2022-09-22 2022-09-22
US63/409,060 2022-09-22
JP2023013779A JP7387926B2 (ja) 2022-02-01 2023-02-01 選択的エストロゲン受容体分解剤の調製のためのプロセス
JP2023138310A JP7805336B2 (ja) 2022-02-01 2023-08-28 選択的エストロゲン受容体分解剤の調製のためのプロセス

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2023138310A Division JP7805336B2 (ja) 2022-02-01 2023-08-28 選択的エストロゲン受容体分解剤の調製のためのプロセス

Publications (2)

Publication Number Publication Date
JP2025183283A JP2025183283A (ja) 2025-12-16
JP2025183283A5 true JP2025183283A5 (https=) 2026-02-10

Family

ID=85382684

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2023013779A Active JP7387926B2 (ja) 2022-02-01 2023-02-01 選択的エストロゲン受容体分解剤の調製のためのプロセス
JP2023138310A Active JP7805336B2 (ja) 2022-02-01 2023-08-28 選択的エストロゲン受容体分解剤の調製のためのプロセス
JP2025146941A Pending JP2025183283A (ja) 2022-02-01 2025-09-04 選択的エストロゲン受容体分解剤の調製のためのプロセス

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2023013779A Active JP7387926B2 (ja) 2022-02-01 2023-02-01 選択的エストロゲン受容体分解剤の調製のためのプロセス
JP2023138310A Active JP7805336B2 (ja) 2022-02-01 2023-08-28 選択的エストロゲン受容体分解剤の調製のためのプロセス

Country Status (15)

Country Link
US (1) US11926634B2 (https=)
EP (1) EP4472982A1 (https=)
JP (3) JP7387926B2 (https=)
KR (2) KR20250006312A (https=)
AU (2) AU2023216654B2 (https=)
CA (1) CA3243621A1 (https=)
CO (1) CO2024009411A2 (https=)
CR (1) CR20240283A (https=)
DO (1) DOP2024000150A (https=)
IL (1) IL313886A (https=)
JO (1) JOP20240169A1 (https=)
MX (1) MX2024009453A (https=)
PE (1) PE20241731A1 (https=)
TW (2) TWI863110B (https=)
WO (1) WO2023150056A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020137965A (ja) * 2019-03-01 2020-09-03 株式会社三洋物産 遊技機
US20240199629A1 (en) * 2022-02-01 2024-06-20 Eli Lilly And Company Processes for the preparation of selective estrogen receptor degraders

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1709021B1 (en) 2004-01-22 2010-08-04 Eli Lilly And Company Selective estrogen receptor modulators for the treatment of vasomotor symptoms
US20080221163A1 (en) 2005-01-18 2008-09-11 Jeffrey Alan Dodge Selective Estrogen Receptor Modulators
EP2343287A1 (en) * 2009-12-10 2011-07-13 Almirall, S.A. New 2-aminothiadiazole derivatives
CN103582637B (zh) * 2011-05-17 2015-08-12 弗·哈夫曼-拉罗切有限公司 酪氨酸激酶抑制剂
BR112015030595A2 (pt) 2013-06-19 2017-07-25 Seragon Pharmaceuticals Inc moduladores de receptor de estrogênio de azetidina e usos dos mesmos
CN107406424B (zh) 2014-12-18 2020-08-25 豪夫迈·罗氏有限公司 雌激素受体调节剂及其用途
MD3820874T2 (ro) 2018-07-12 2023-05-31 Lilly Co Eli Degradanți selectivi ai receptorului estrogen
TWI702219B (zh) 2018-07-12 2020-08-21 美商美國禮來大藥廠 選擇性雌激素受體降解劑
US11014915B2 (en) * 2019-07-22 2021-05-25 Sun Pharma Advanced Research Company Limited Selective estrogen receptor degrader
CN115175679A (zh) 2020-03-06 2022-10-11 奥列马制药公司 治疗雌激素受体相关疾病的方法
CN115867282B (zh) * 2020-03-26 2025-05-27 奈克斯拉制药英国有限公司 用于抗癌的5-氨基-8-(4-吡啶基)-[1,2,4]三唑并[4,3-c]嘧啶-3-酮化合物
AR123185A1 (es) * 2020-08-10 2022-11-09 Novartis Ag Compuestos y composiciones para inhibir ezh2
TWI837605B (zh) 2021-03-09 2024-04-01 美商美國禮來大藥廠 使用serd組合給藥方案治療癌症之方法
TWI894443B (zh) 2021-03-16 2025-08-21 美商美國禮來大藥廠 選擇性雌激素受體降解劑

Similar Documents

Publication Publication Date Title
JP2025183283A5 (https=)
JP2020169171A5 (https=)
JP2021530451A5 (https=)
CN113906013A (zh) 吡啶氮氧化合物及其制备方法和用途
EP0287690B1 (de) Stabile Lösungsmitteladdukte von Z-1-(p-beta-Dimethylamino-ethoxyphenyl)-1-(p-hydroxyphenyl)-2-phenylbut-1-en
RU2017134551A (ru) Новые дигидропиридоизохинолиноны и их фармацевтические композиции для лечения воспалительных расстройств
JP2023002516A5 (https=)
CA2506082A1 (en) Novel medicaments for the treatment of chronic obstructive pulmonary disease
JP2006514012A5 (https=)
JP2013541502A5 (https=)
JP2011502174A5 (https=)
JPWO2023099592A5 (https=)
BR112022022281A2 (pt) Misturas e composições compreendendo 5-fluoro-4-imino-3-metil- 1-tosil-3,4-dihidropirimidin-2-ona e métodos de uso das mesmas
JP2017522304A5 (https=)
JP2004502732A5 (https=)
DE69705421T2 (de) 15-fluoro-prostaglandine als augendrucksenkende mittel
JPWO2022221227A5 (https=)
JPWO2019149164A5 (https=)
JPWO2021237207A5 (https=)
JP2025142197A5 (https=)
JPWO2022212489A5 (https=)
JP2010505869A5 (https=)
KR101853718B1 (ko) 코지산 유도체 제조 방법
CZ294365B6 (cs) Deriváty kolchicinu, způsob výroby a farmaceutický prostředek
AR029399A1 (es) Compuestos derivados del benzofurano, una composicion farmaceutica, y el uso de dichos compuestos para la manufactura de un medicamento o una sal farmaceuticamente aceptable para el tratamiento de arritmias cardiacas